Anti-NYX/ CLRP/ CSNB1 functional antibody

Anti-NYX/ CLRP/ CSNB1 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to NYX/NYX products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0382-Ab-1/ GM-Tg-hg-SE0382-Ab-2Anti-Human NYX monoclonal antibodyHuman
GM-Tg-rg-SE0382-Ab-1/ GM-Tg-rg-SE0382-Ab-2Anti-Rat NYX monoclonal antibodyRat
GM-Tg-mg-SE0382-Ab-1/ GM-Tg-mg-SE0382-Ab-2Anti-Mouse NYX monoclonal antibodyMouse
GM-Tg-cynog-SE0382-Ab-1/ GM-Tg-cynog-SE0382-Ab-2Anti-Cynomolgus/ Rhesus macaque NYX monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0382-Ab-1/ GM-Tg-felg-SE0382-Ab-2Anti-Feline NYX monoclonal antibodyFeline
GM-Tg-cang-SE0382-Ab-1/ GM-Tg-cang-SE0382-Ab-2Anti-Canine NYX monoclonal antibodyCanine
GM-Tg-bovg-SE0382-Ab-1/ GM-Tg-bovg-SE0382-Ab-2Anti-Bovine NYX monoclonal antibodyBovine
GM-Tg-equg-SE0382-Ab-1/ GM-Tg-equg-SE0382-Ab-2Anti-Equine NYX monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0382-Ab-1/ GM-Tg-hg-SE0382-Ab-2; GM-Tg-rg-SE0382-Ab-1/ GM-Tg-rg-SE0382-Ab-2;
GM-Tg-mg-SE0382-Ab-1/ GM-Tg-mg-SE0382-Ab-2; GM-Tg-cynog-SE0382-Ab-1/ GM-Tg-cynog-SE0382-Ab-2;
GM-Tg-felg-SE0382-Ab-1/ GM-Tg-felg-SE0382-Ab-2; GM-Tg-cang-SE0382-Ab-1/ GM-Tg-cang-SE0382-Ab-2;
GM-Tg-bovg-SE0382-Ab-1/ GM-Tg-bovg-SE0382-Ab-2; GM-Tg-equg-SE0382-Ab-1/ GM-Tg-equg-SE0382-Ab-2
Products NameAnti-NYX monoclonal antibody
Formatmab
Target NameNYX
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NYX benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0382-Ag-1Recombinant multi-species NYX/ CLRP/ CSNB1 protein


    Target information

    Target IDGM-SE0382
    Target NameNYX
    Gene ID60506,236690,302516,700641,111094865,101086042,101904567,111771636
    Gene Symbol and SynonymsCLNP,CLRP,CSNB1,CSNB1A,CSNB4,LOC111094865,NBM1,nob,NYX,RGD1561300,SLRN
    Uniprot AccessionQ9GZU5
    Uniprot Entry NameNYX_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000188937
    Target ClassificationN/A

    The target: NYX, gene name: NYX, also named as CLRP, CSNB1, CSNB1A, CSNB4, NBM1. The product of this gene belongs to the small leucine-rich proteoglycan (SLRP) family of proteins. Defects in this gene are the cause of congenital stationary night blindness type 1 (CSNB1), also called X-linked congenital stationary night blindness (XLCSNB). CSNB1 is a rare inherited retinal disorder characterized by impaired scotopic vision, myopia, hyperopia, nystagmus and reduced visual acuity. The role of other SLRP proteins suggests that mutations in this gene disrupt developing retinal interconnections involving the ON-bipolar cells, leading to the visual losses seen in patients with complete CSNB. [provided by RefSeq, Oct 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.